HMB (β-Hydroxy-β-methylbutyrate)

Our opinion on this compoundEstablished workhorse

37/100

Mature anti-catabolic metabolite with real catabolic-state signal but low novelty as a research target

Look, HMB has been around since the early 1990s, and the core story hasn’t changed much. It’s a metabolite of leucine, produced via alpha-ketoisocaproate during roughly 5% of leucine catabolism, and the proposed mechanism is straightforward: reduce protein breakdown through ubiquitin-proteasome pathway inhibition while nudging mTOR signaling upward. Thats a real mechanism. Just not a particularly exciting one. We’ve known how the proteasome works for decades, and HMB’s interaction with it is well-characterized to the point of being textbook.

The evidence picture is better than you’d expect from something marketed this aggressively. In catabolic states, the signal is genuine. HIV wasting trials, cancer cachexia cohorts, bedrest-induced atrophy protocols, and post-surgical recovery studies all show meaningful lean mass preservation at 3 g/day. The Vukovich group, Flakoll et al., and several independent labs replicated this in sarcopenic and hospitalized populations. That is the compound at its best. In healthy resistance-trained athletes, the effect size compresses fast. The meta-analyses in athletic populations are messy, and the dramatic early claims from Wilson et al. didn’t survive independent replication at scale.

The free acid form (HMB-FA) has better pharmacokinetics than the calcium salt, faster absorption and higher peak plasma concentration. Interesting story in theory. But most of the foundational clinical work used Ca-HMB, so the HMB-FA literature is thinner, and the practical effect-size advantage looks modest when you read the head-to-head data carefully. Not a reason to deprioritize the compound, but not a reason to get excited either.

What we don’t like about HMB as a research target: the mechanism doesn’t point at anything that isn’t already well-mapped. If you’re trying to understand proteasome biology, you’re reaching for more specific chemical probes. If you’re trying to build an anti-catabolic protocol, you’re comparing HMB to leucine supplementation, essential amino acid formulations, and the newer mitochondrial peptide work, and HMB doesn’t come out ahead on bench utility. The probe value is real but narrow. It works best as a comparator arm in muscle-wasting trial design. That’s about its ceiling.

For investigators in catabolic biology, it earns a place as a reference compound: well-sourced, defined pharmacokinetics, clean mechanism. For anyone focused on the frontier of muscle-sparing or anti-aging research, the interesting signals are coming from myostatin pathway modulators, mitochondrial peptides, and GLP-1 adjacent compounds. HMB is the baseline you measure against, not the signal you’re chasing. Honest assessment: score this one and move on.

Novelty: 22
Mechanism promise: 28
In-category differentiation: 35
Evidence quality: 52
Translational signal: 52
Research bench value: 40

Rationale HMB lands just under the foundational-metabolite ceiling on its own calculated merit: the catabolic-state evidence base is genuine and multi-lab replicated, but the mechanism is unremarkable, novelty is low, and differentiation from leucine itself or EAA protocols is modest. No cap binds because the axes score it there naturally.

Leucine metabolite (anti-catabolic supplement)

Beta-hydroxy-beta-methylbutyrate; a leucine metabolite that reduces muscle protein breakdown; used in catabolic states and as a supplement.

Abstract

HMB (beta-hydroxy-beta-methylbutyric acid; CAS 625-08-1; molecular formula C5H10O3; molecular weight 118.13; Ca-HMB salt CAS 135236-72-5) is a metabolite of the branched-chain amino acid leucine, produced by approximately 5 percent of leucine catabolism via alpha-ketoisocaproate. Mechanism: HMB reduces muscle protein breakdown via inhibition of the ubiquitin-proteasome pathway and enhanced cell membrane integrity; secondary effects on muscle protein synthesis through mTOR pathway activation. The clinical evidence is strongest in catabolic states (HIV wasting, cancer cachexia, sarcopenia of aging, bedrest, post-surgical recovery) where 3 g/day reduces protein breakdown and preserves lean mass. In healthy resistance-trained athletes, the effect is small. The free acid form (HMB-FA) has improved pharmacokinetics over the calcium salt (Ca-HMB) but most research uses Ca-HMB. Plasma half-life is approximately 2 hours. Used as a reference anti-catabolic supplement.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-399Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.